NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Otonomy Inc (NASDAQ: OTIC)

OTIC Technical Analysis
As on 11th Apr 2023 OTIC SHARE Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.80 & Strong Sell for SHORT-TERM with Stoploss of 2.11 we also expect STOCK to react on Following IMPORTANT LEVELS.


Open 0.02 Change Price %
High 0.02 1 Day -0.11 -91.67
Low 0.01 1 Week -0.11 -91.67
Close 0.01 1 Month -0.10 -90.91
Volume 1943468 1 Year -1.85 -99.46
52 Week High 2.51 | 52 Week Low 0.07
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
Daily Charts
Intraday Charts
Whats New @
Free Analysis
OTIC Important Levels Intraday
OTIC Forecast February 2024
4th UP Forecast0.84
3rd UP Forecast0.57
2nd UP Forecast0.41
1st UP Forecast0.24
1st DOWN Forecast-0.22
2nd DOWN Forecast-0.39
3rd DOWN Forecast-0.55
4th DOWN Forecast-0.82
OTIC Weekly Forecast
4th UP Forecast0.59
3rd UP Forecast0.40
2nd UP Forecast0.29
1st UP Forecast0.17
1st DOWN Forecast-0.15
2nd DOWN Forecast-0.27
3rd DOWN Forecast-0.38
4th DOWN Forecast-0.57
OTIC Forecast2024
4th UP Forecast4.98
3rd UP Forecast3.39
2nd UP Forecast2.4
1st UP Forecast1.42
1st DOWN Forecast-1.4
2nd DOWN Forecast-2.38
3rd DOWN Forecast-3.37
4th DOWN Forecast-4.96
OTIC Other Details
Segment EQ
Market Capital 119597536.00
Sector Healthcare
Industry Biotechnology
Offical website >
OTIC Address
OTIC Latest News
Your Comments and Response on Otonomy Inc
OTIC Business Profile
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Address: 4796 Executive Drive, San Diego, CA, United States, 92121
2005-2023 All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service